The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cell Line Development for Biologics Market Research Report 2025
Synopsis
Cell line development is a critical step in the production of biologics. Biologics are complex molecules that are produced by living cells, such as proteins, antibodies, and vaccines. To produce biologics in large quantities, scientists need to develop cell lines that can produce these molecules consistently and at high levels.
Global Cell Line Development for Biologics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cell Line Development for Biologics market research.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Segment by Application
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cell Line Development for Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Cell line development is a critical step in the production of biologics. Biologics are complex molecules that are produced by living cells, such as proteins, antibodies, and vaccines. To produce biologics in large quantities, scientists need to develop cell lines that can produce these molecules consistently and at high levels.
Global Cell Line Development for Biologics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cell Line Development for Biologics market research.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Segment by Application
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cell Line Development for Biologics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell Line Development for Biologics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CHO Cell Lines
1.2.3 HEK293 Cell Lines
1.2.4 Insect Cell Lines
1.3 Market by Application
1.3.1 Global Cell Line Development for Biologics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Monoclonal Antibodies
1.3.3 Recombinant Proteins
1.3.4 Vaccines
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell Line Development for Biologics Market Perspective (2018-2029)
2.2 Cell Line Development for Biologics Growth Trends by Region
2.2.1 Global Cell Line Development for Biologics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cell Line Development for Biologics Historic Market Size by Region (2018-2023)
2.2.3 Cell Line Development for Biologics Forecasted Market Size by Region (2024-2029)
2.3 Cell Line Development for Biologics Market Dynamics
2.3.1 Cell Line Development for Biologics Industry Trends
2.3.2 Cell Line Development for Biologics Market Drivers
2.3.3 Cell Line Development for Biologics Market Challenges
2.3.4 Cell Line Development for Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell Line Development for Biologics Players by Revenue
3.1.1 Global Top Cell Line Development for Biologics Players by Revenue (2018-2023)
3.1.2 Global Cell Line Development for Biologics Revenue Market Share by Players (2018-2023)
3.2 Global Cell Line Development for Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell Line Development for Biologics Revenue
3.4 Global Cell Line Development for Biologics Market Concentration Ratio
3.4.1 Global Cell Line Development for Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell Line Development for Biologics Revenue in 2022
3.5 Cell Line Development for Biologics Key Players Head office and Area Served
3.6 Key Players Cell Line Development for Biologics Product Solution and Service
3.7 Date of Enter into Cell Line Development for Biologics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell Line Development for Biologics Breakdown Data by Type
4.1 Global Cell Line Development for Biologics Historic Market Size by Type (2018-2023)
4.2 Global Cell Line Development for Biologics Forecasted Market Size by Type (2024-2029)
5 Cell Line Development for Biologics Breakdown Data by Application
5.1 Global Cell Line Development for Biologics Historic Market Size by Application (2018-2023)
5.2 Global Cell Line Development for Biologics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cell Line Development for Biologics Market Size (2018-2029)
6.2 North America Cell Line Development for Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cell Line Development for Biologics Market Size by Country (2018-2023)
6.4 North America Cell Line Development for Biologics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell Line Development for Biologics Market Size (2018-2029)
7.2 Europe Cell Line Development for Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cell Line Development for Biologics Market Size by Country (2018-2023)
7.4 Europe Cell Line Development for Biologics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell Line Development for Biologics Market Size (2018-2029)
8.2 Asia-Pacific Cell Line Development for Biologics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cell Line Development for Biologics Market Size by Region (2018-2023)
8.4 Asia-Pacific Cell Line Development for Biologics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell Line Development for Biologics Market Size (2018-2029)
9.2 Latin America Cell Line Development for Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cell Line Development for Biologics Market Size by Country (2018-2023)
9.4 Latin America Cell Line Development for Biologics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell Line Development for Biologics Market Size (2018-2029)
10.2 Middle East & Africa Cell Line Development for Biologics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cell Line Development for Biologics Market Size by Country (2018-2023)
10.4 Middle East & Africa Cell Line Development for Biologics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Cell Line Development for Biologics Introduction
11.1.4 Lonza Revenue in Cell Line Development for Biologics Business (2018-2023)
11.1.5 Lonza Recent Development
11.2 Corning
11.2.1 Corning Company Detail
11.2.2 Corning Business Overview
11.2.3 Corning Cell Line Development for Biologics Introduction
11.2.4 Corning Revenue in Cell Line Development for Biologics Business (2018-2023)
11.2.5 Corning Recent Development
11.3 Sartorius
11.3.1 Sartorius Company Detail
11.3.2 Sartorius Business Overview
11.3.3 Sartorius Cell Line Development for Biologics Introduction
11.3.4 Sartorius Revenue in Cell Line Development for Biologics Business (2018-2023)
11.3.5 Sartorius Recent Development
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Detail
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Cell Line Development for Biologics Introduction
11.4.4 Thermo Fisher Scientific Revenue in Cell Line Development for Biologics Business (2018-2023)
11.4.5 Thermo Fisher Scientific Recent Development
11.5 Selexis
11.5.1 Selexis Company Detail
11.5.2 Selexis Business Overview
11.5.3 Selexis Cell Line Development for Biologics Introduction
11.5.4 Selexis Revenue in Cell Line Development for Biologics Business (2018-2023)
11.5.5 Selexis Recent Development
11.6 Beckman Coulter (Danaher )
11.6.1 Beckman Coulter (Danaher ) Company Detail
11.6.2 Beckman Coulter (Danaher ) Business Overview
11.6.3 Beckman Coulter (Danaher ) Cell Line Development for Biologics Introduction
11.6.4 Beckman Coulter (Danaher ) Revenue in Cell Line Development for Biologics Business (2018-2023)
11.6.5 Beckman Coulter (Danaher ) Recent Development
11.7 CYTENA
11.7.1 CYTENA Company Detail
11.7.2 CYTENA Business Overview
11.7.3 CYTENA Cell Line Development for Biologics Introduction
11.7.4 CYTENA Revenue in Cell Line Development for Biologics Business (2018-2023)
11.7.5 CYTENA Recent Development
11.8 Molecular Devices
11.8.1 Molecular Devices Company Detail
11.8.2 Molecular Devices Business Overview
11.8.3 Molecular Devices Cell Line Development for Biologics Introduction
11.8.4 Molecular Devices Revenue in Cell Line Development for Biologics Business (2018-2023)
11.8.5 Molecular Devices Recent Development
11.9 Samsung Biologics
11.9.1 Samsung Biologics Company Detail
11.9.2 Samsung Biologics Business Overview
11.9.3 Samsung Biologics Cell Line Development for Biologics Introduction
11.9.4 Samsung Biologics Revenue in Cell Line Development for Biologics Business (2018-2023)
11.9.5 Samsung Biologics Recent Development
11.10 Hera BioLabs
11.10.1 Hera BioLabs Company Detail
11.10.2 Hera BioLabs Business Overview
11.10.3 Hera BioLabs Cell Line Development for Biologics Introduction
11.10.4 Hera BioLabs Revenue in Cell Line Development for Biologics Business (2018-2023)
11.10.5 Hera BioLabs Recent Development
11.11 GTP Bioways
11.11.1 GTP Bioways Company Detail
11.11.2 GTP Bioways Business Overview
11.11.3 GTP Bioways Cell Line Development for Biologics Introduction
11.11.4 GTP Bioways Revenue in Cell Line Development for Biologics Business (2018-2023)
11.11.5 GTP Bioways Recent Development
11.12 Abzena
11.12.1 Abzena Company Detail
11.12.2 Abzena Business Overview
11.12.3 Abzena Cell Line Development for Biologics Introduction
11.12.4 Abzena Revenue in Cell Line Development for Biologics Business (2018-2023)
11.12.5 Abzena Recent Development
11.13 FyoniBio
11.13.1 FyoniBio Company Detail
11.13.2 FyoniBio Business Overview
11.13.3 FyoniBio Cell Line Development for Biologics Introduction
11.13.4 FyoniBio Revenue in Cell Line Development for Biologics Business (2018-2023)
11.13.5 FyoniBio Recent Development
11.14 Catalent
11.14.1 Catalent Company Detail
11.14.2 Catalent Business Overview
11.14.3 Catalent Cell Line Development for Biologics Introduction
11.14.4 Catalent Revenue in Cell Line Development for Biologics Business (2018-2023)
11.14.5 Catalent Recent Development
11.15 WuXi Biologics
11.15.1 WuXi Biologics Company Detail
11.15.2 WuXi Biologics Business Overview
11.15.3 WuXi Biologics Cell Line Development for Biologics Introduction
11.15.4 WuXi Biologics Revenue in Cell Line Development for Biologics Business (2018-2023)
11.15.5 WuXi Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
